Catalent Biologics increased capacity at its Bloomington, IN Facility.
Catalent announced in an April 23, 2020 press release that it completed its $14 million expansion to increase the biologics packaging capabilities and capacity at its Bloomington, IN facility. The company added 15,000-ft2 of packaging infrastructure to the existing biologics and sterile manufacturing site, including five new packaging suites and a new quality control laboratory.
Three new packaging lines include an Optima combination syringe assembly machine, an automated Mikron auto-injector assembly machine, and a Dividella NeoTOP x (NTX) top-load cartoner with both semi-automated and fully-automated configurations. All three high-speed lines are fully qualified and ready to provide customers faster and more flexible packaging solutions for vials, syringes, and devices with no glass-to-glass contact.
“The completion of this expansion marks a major milestone for our late-stage and commercial customers, allowing Catalent to focus on more complex device assembly and packaging needs for biologic products at higher volumes,” commented Mike Riley, region president, Biologics North America, in the press release. “This state-of-the-art equipment adds to our growing network of global packaging capabilities alongside our Brussels, Belgium, and Anagni, Italy drug product manufacturing sites.”
Source: Catalent
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.